What You Should Know:
– CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment.
– The digital health partnership extends across therapeutic areas, including immunology, hematology and respiratory, among others.
BrightInsight, Inc., a provider of the regulated IoT platform for biopharma and medtech, and CSL Behring, a leading biotechnology company, announced a global digital health partnership to provide digitally-enhanced treatment experiences and regulated digital health offerings to support CSL Behring therapies. CSL Behring selected the regulated BrightInsight Platform to manage and support its growing digital health portfolio of solutions focused on enhancing the treatment experiences of patients with rare and serious diseases.
Built under a robust Quality Management System to support regulated use cases, the BrightInsight Platform enables CSL Behring to develop and host digital health devices, apps, algorithms, and Software as a Medical Device (SaMD) at scale while maintaining compliance with privacy, security and regulatory requirements across the globe. CSL Behring is leveraging the BrightInsight Platform enterprise-wide as its common platform infrastructure to centralize its digital projects without limiting localization, customization or scalability.
Developing Holistic & Integrated Therapeutic Solutions
Leveraging the BrightInsight Platform built on Google Cloud, CSL Behring will develop holistic and integrated therapeutic solutions that elevate the lives of patients by enabling them to manage their condition with independence, confidence, and control. The partnership extends across therapeutic areas, including immunology, hematology, and respiratory, among others.
COVID-19 has shown that digital health has the potential to alleviate some of the biggest concerns in healthcare today—including the reliance on traditional healthcare settings and face-to-face care visits. For many of CSL Behring’s patients, treatment includes infusions that require an in-person nurse visit. Many of these patients are also at higher-risk for coronavirus, especially those with respiratory diseases. Digital health solutions that enhance treatment experiences and enable patients to manage their condition with more independence are more important than ever.
This is the fourth global biopharmaceutical company to select BrightInsight, following AstraZeneca, Novo Nordisk and F. Hoffmann-La Roche.
“We are excited to partner with the team at CSL Behring to optimize their transformational therapies through our regulated digital platform to seek to improve patient experiences and clinical outcomes,” said Kal Patel, MD, CEO & Co-Founder, BrightInsight. “This latest global partnership with a biopharmaceutical leader represents an important next step in achieving our mission to transform patient outcomes globally through the power of digital technology.”
